InsidersTradesSigma
Follow the 奥浦迈 share price and the full management transaction log of the company, a listed equity based in China. Shares trade on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 奥浦迈 has published 24 public disclosures. Market capitalisation: €7.4bn. The latest transaction was reported on 25 December 2024 (Purchase). Among the most active insiders: 肖志华. The full history is accessible without an account.
24
Insider Decl.
n/a
Thresholds
€1m
24 ops.
Buy Volume
n/a
n/a
Sell Volume
18Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,690 of 28,957 companies
51.6
score / 100
Value39
Quality64
FCF yld0.6%
Earn yld0.6%
EV/EBITDA·
ROE2.6%
Gross mgn51%
Net mgn12%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 December 2024
Declarations24 total
24 of 24 declarations
About 奥浦迈
奥浦迈 is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative pharmaceutical products.